Valuation: Zai Lab Limited

Market Cap 2.3B 2.02B 1.86B 1.72B 3.26B 220B 3.31B 22.22B 8.71B 108B 8.64B 8.46B 372B P/E 2026 *
-9.25x
P/E 2027 * -11x
Enterprise Value 1.86B 1.63B 1.5B 1.39B 2.63B 177B 2.67B 17.94B 7.04B 87.33B 6.98B 6.83B 301B EV / Sales 2026 *
4.14x
EV / Sales 2027 * 3.22x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day+4.19%
1 week+6.75%
Current month+10.13%
1 month+27.01%
3 months+0.58%
6 months+12.26%
Current year+19.18%
1 week 16.2
Extreme 16.2
17.4
1 month 14.4
Extreme 14.4
17.4
Current year 13.2
Extreme 13.2
21
1 year 13.2
Extreme 13.2
34.2
3 years 12.4
Extreme 12.4
38.2
5 years 12.4
Extreme 12.4
146
10 years 12.4
Extreme 12.4
162
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
+4.19%+6.75% - - 2.3B
-0.51%+1.57%+18.72%-5.52% 67.61B
-5.16%-8.63%+37.37%+202.27% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-49.30%-53.47% 40.94B
+0.12%-7.85%+47.16%-29.27% 29.4B
-10.83%-14.41%+99.15%-44.54% 27.09B
-1.53%-0.13%+65.92%+88.58% 23.32B
+3.88%+2.16%+11.78%+201.51% 19.89B
-1.59%-1.63%+61.04%+130.75% 16.91B
Average -0.82%-3.02%+36.81%+58.87% 35.53B
Weighted average by Cap. -1.32%-2.83%+30.49%+49.38%

Financials

2026 *2027 *
Net sales 449M 393M 362M 335M 635M 42.79B 646M 4.33B 1.7B 21.08B 1.68B 1.65B 72.54B 596M 522M 481M 445M 843M 56.8B 857M 5.75B 2.25B 27.98B 2.24B 2.19B 96.29B
Net income -241M -211M -195M -180M -341M -22.97B -347M -2.32B -912M -11.32B -904M -885M -38.95B -156M -137M -126M -117M -221M -14.92B -225M -1.51B -592M -7.35B -587M -575M -25.3B
Net Debt -443M -388M -358M -331M -627M -42.26B -638M -4.28B -1.68B -20.82B -1.66B -1.63B -71.64B -387M -339M -313M -289M -548M -36.93B -557M -3.74B -1.47B -18.19B -1.45B -1.42B -62.6B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change
10/07/26 €17.40 +4.19%
09/07/26 €16.70 +2.45%
08/07/26 €16.30 +0.62%
07/07/26 €16.20 0.00%
06/07/26 €16.20 -0.61%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
20.49USD
Average target price
33.30USD
Spread / Average Target
+62.53%

Quarterly revenue - Rate of surprise